Compare Stocks: TEVA, ABBV, NVO, and PFE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$266.65 +0.3%	$258.12	$190.75 ▼ $269.39	$469.54B	0.24	4.42 million shs	4.50 million shs
NVO Novo Nordisk A/S	$37.49 -0.1%	$44.12	$35.12 ▼ $64.16	$167.62B	0.76	14.68 million shs	13.68 million shs
PFE Pfizer	$27.48 +0.3%	$27.50	$23.62 ▼ $29.21	$156.23B	0.32	32.86 million shs	24.03 million shs
TEVA Teva Pharmaceutical Industries	$39.05 -1.5%	$37.35	$18.83 ▼ $40.79	$46.22B	0.89	4.92 million shs	5.72 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.27%	+1.18%	+4.05%	+5.40%	+15.79%
NVO Novo Nordisk A/S	-0.15%	-2.15%	-19.53%	-23.27%	-37.17%
PFE Pfizer	+0.24%	-4.27%	-3.31%	+14.28%	+3.89%
TEVA Teva Pharmaceutical Industries	-1.45%	-1.99%	+7.39%	+17.43%	+95.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$266.65 +0.3%	$258.12	$190.75 ▼ $269.39	$469.54B	0.24	4.42 million shs	4.50 million shs
NVO Novo Nordisk A/S	$37.49 -0.1%	$44.12	$35.12 ▼ $64.16	$167.62B	0.76	14.68 million shs	13.68 million shs
PFE Pfizer	$27.48 +0.3%	$27.50	$23.62 ▼ $29.21	$156.23B	0.32	32.86 million shs	24.03 million shs
TEVA Teva Pharmaceutical Industries	$39.05 -1.5%	$37.35	$18.83 ▼ $40.79	$46.22B	0.89	4.92 million shs	5.72 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.27%	+1.18%	+4.05%	+5.40%	+15.79%
NVO Novo Nordisk A/S	-0.15%	-2.15%	-19.53%	-23.27%	-37.17%
PFE Pfizer	+0.24%	-4.27%	-3.31%	+14.28%	+3.89%
TEVA Teva Pharmaceutical Industries	-1.45%	-1.99%	+7.39%	+17.43%	+95.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.83	Moderate Buy	$273.82	2.69% Upside
NVO Novo Nordisk A/S	2.07	Hold	$102.85	174.34% Upside
PFE Pfizer	2.14	Hold	$28.56	3.91% Upside
TEVA Teva Pharmaceutical Industries	2.92	Moderate Buy	$44.67	14.39% Upside

Current Analyst Ratings Breakdown

Latest TEVA, ABBV, NVO, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	PFE Pfizer	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
10/6/2026	ABBV AbbVie	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$280.00 ➝ $320.00
10/6/2026	ABBV AbbVie	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
10/6/2026	ABBV AbbVie	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Outperform	$280.00 ➝ $320.00
10/1/2026	TEVA Teva Pharmaceutical Industries	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
9/29/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/29/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/23/2026	TEVA Teva Pharmaceutical Industries	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
9/22/2026	NVO Novo Nordisk A/S	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell	$38.00
9/21/2026	NVO Novo Nordisk A/S	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/21/2026	NVO Novo Nordisk A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	7.70	$15.19 per share	17.55	($1.83) per share	-145.71
NVO Novo Nordisk A/S	$46.80B	3.58	$4.68 per share	8.01	$6.58 per share	5.70
PFE Pfizer	$62.58B	2.50	$4.41 per share	6.23	$15.26 per share	1.80
TEVA Teva Pharmaceutical Industries	$17.26B	2.64	$3.67 per share	10.63	$6.88 per share	5.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	75.32	16.54	1.20	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	9.17	10.99	1.23	35.36%	58.61%	20.91%	11/4/2026 (Estimated)
PFE Pfizer	$7.77B	$0.76	36.16	9.32	1.84	6.80%	19.63%	8.46%	11/3/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	65.08	13.02	3.78	4.08%	32.64%	6.34%	11/3/2026 (Estimated)

Latest TEVA, ABBV, NVO, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	NVO Novo Nordisk A/S	$0.7590	N/A	N/A	N/A	$11.12 billion	N/A
11/3/2026	Q3 2026	PFE Pfizer	$0.7520	N/A	N/A	N/A	$15.90 billion	N/A
11/3/2026	Q3 2026	TEVA Teva Pharmaceutical Industries	$0.71	N/A	N/A	N/A	$4.21 billion	N/A
10/30/2026	Q3 2026	ABBV AbbVie	$3.86	N/A	N/A	N/A	$17.31 billion	N/A
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.60%	+6.80%	195.48%	53 Years
NVO Novo Nordisk A/S	$0.82	2.19%	+21.74%	20.05%	N/A
PFE Pfizer	$1.72	6.26%	-13.20%	226.32%	16 Years
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest TEVA, ABBV, NVO, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/6/2026	PFE Pfizer	quarterly	$0.43	6.26%	11/6/2026	11/6/2026	12/7/2026
9/10/2026	ABBV AbbVie	quarterly	$1.73	2.71%	10/15/2026	10/15/2026	11/16/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
NVO Novo Nordisk A/S	0.55	0.87	0.66
PFE Pfizer	0.71	1.27	0.96
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.62%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

TEVA, ABBV, NVO, and PFE Headlines

Recent News About These Companies

Teva Pharmaceutical Industries stock tracks DEGEVMA FDA approval

October 5 at 3:07 PM | ad-hoc-news.deA

What You Need to Know Ahead of Deckers Outdoor’s Earnings Release

October 5 at 3:07 PM | barchart.com

Teva Pharmaceutical Industries stock gains as biosimilar deal expands

October 4 at 12:25 PM | ad-hoc-news.deA

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Picked Up by Analysts at TD Cowen

October 3, 2026 | americanbankingnews.com

Teva's Ecopipam Shows Sustained Tic Reduction In Pediatric Tourette Syndrome

October 2, 2026 | rttnews.com

Consensus price target for Teva Pharmaceutical Industries raised 24.24% to ₪41.82

October 2, 2026 | msn.com

Teva Pharmaceutical Industries Ltd: Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

October 2, 2026 | finanznachrichten.de

Teva Pharmaceutical Industries Limited - Depositary receipt price target increased by 19.98% to $0.13

October 2, 2026 | msn.com

Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome

October 2, 2026 | rttnews.com

Teva Pharmaceutical Industries Ltd: Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism ...

October 2, 2026 | finanznachrichten.de

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

October 2, 2026 | finance.yahoo.com

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

October 2, 2026 | finance.yahoo.com

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

October 2, 2026 | globenewswire.com

Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

October 2, 2026 | globenewswire.com

Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion

October 1, 2026 | insidermonkey.com

Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates

October 1, 2026 | marketscreener.comM

Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates

October 1, 2026 | koreatimes.co.krK

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

October 1, 2026 | finance.yahoo.com

TD Cowen Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

October 1, 2026 | marketbeat.com

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

October 1, 2026 | businesswire.com

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

September 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TEVA, ABBV, NVO, and PFE Company Descriptions

AbbVie NYSE:ABBV

$266.65 +0.89 (+0.33%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$267.32 +0.68 (+0.25%)

As of 07:39 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Novo Nordisk A/S NYSE:NVO

$37.49 -0.05 (-0.13%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$37.51 +0.02 (+0.05%)

As of 07:42 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$27.48 +0.07 (+0.26%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$27.62 +0.13 (+0.49%)

As of 07:42 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$39.05 -0.61 (-1.54%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$38.62 -0.43 (-1.11%)

As of 07:41 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, ABBV, NVO, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, ABBV, NVO, and PFE Earnings

Compare Dividends

Latest TEVA, ABBV, NVO, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, ABBV, NVO, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TEVA, ABBV, NVO, and PFE Company Descriptions

AbbVie NYSE:ABBV

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools